Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the seven major markets under study throughout the ten-year forecast period. However, treatment of cancer-related pain will not change dramatically over the next decade because of a dearth of new therapies. Indeed, strong opioid analgesics will continue to be the mainstay of treatment for severe types of cancer pain, accounting for more than 90% of major-market drug sales for cancer pain in 2014 and 2024. Overall, we expect only modest growth in the $2 billion cancer pain market throughout our ten-year forecast period.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 51 country-specific interviews with thought-leading physicians, including pain specialists, palliative care specialists, anesthesiologists, oncologists, and neurologists.
Epidemiology: Prevalent cases of severe cancer pain, breakthrough cancer pain, neuropathic cancer pain, and metastatic bone pain.
Emerging therapies: Phase II: 7 drugs; Phase III or preregistration: 8 drugs.
Market forecast features: Top-down market features prescription drug treatment for severe, breakthrough, neuropathic, and metastatic bone pain in cancer patients in the seven major markets under study for 2014, with forecast drug sales for 2019 (mid-year) and 2024 (final forecast year).